WuXi XDC Cayman Inc. (FRA:L74)

Market Cap	10.28B +9.1%
Revenue (ttm)	894.88M +36.5%
Net Income	200.25M +17.1%
EPS	0.15 +12.8%
Shares Out	n/a
PE Ratio	51.25
Forward PE	31.66
Dividend	n/a
Ex-Dividend Date	n/a

Volume	777
Open	7.70
Previous Close	8.55
Day's Range	7.70 - 7.75
52-Week Range	4.90 - 9.50
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Oct 29, 2026

About WuXi XDC Cayman

WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of the drug substances and drug products of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. It also provides international sales contracting services. Additionally, the company engages in the research and development, m...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2013
• Employees: 3,628
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: L74

Financial Performance

In 2025, WuXi XDC Cayman's revenue was 5.94 billion, an increase of 46.69% compared to the previous year's 4.05 billion. Earnings were 1.48 billion, an increase of 38.41%.

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 23, 2026

Data Sources Report a data error